Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference
01 févr. 2024 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the Guggenheim 6th Annual Biotechnology Conference on...
Travere Therapeutics Provides Corporate Update and 2024 Outlook
08 janv. 2024 07h00 HE
|
Travere Therapeutics, Inc.
Received 459 new patient start forms for FILSPARI® (sparsentan) in the fourth quarter of 2023; preliminary net product sales of FILSPARI totaled $15 million for the fourth quarter Company on track to...
Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 janv. 2024 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the 42nd Annual...
Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
21 nov. 2023 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the 6th Annual Evercore ISI HealthCONx Conference on...
Travere Therapeutics Reports Third Quarter 2023 Financial Results
07 nov. 2023 16h01 HE
|
Travere Therapeutics, Inc.
Received 430 new patient start forms for FILSPARI® (sparsentan) in the third quarter of 2023; demand and payer coverage continued to grow Net product sales of FILSPARI totaled...
Travere Therapeutics to Report Third Quarter 2023 Financial Results
24 oct. 2023 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2023 financial results on Tuesday, November 7, 2023, after the...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 oct. 2023 17h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2023, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 sept. 2023 17h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on September 10, 2023, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference
31 août 2023 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the 2023 Wells Fargo Healthcare Conference on Thursday,...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14 août 2023 17h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on August 10, 2023, the Compensation Committee of its Board of Directors granted...